Zhang Pengyu, Xiao Jun, Ruan Yingxin, Zhang Zhenzhen, Zhang Xuejun
Department of Blood Transfusion, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin 300060, People's Republic of China.
Department of Immunology, Key Laboratory of Educational Ministry of China, Tianjin Key Laboratory of Cellular and Molecular Immunology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, People's Republic of China.
Cancer Manag Res. 2020 Jun 18;12:4667-4675. doi: 10.2147/CMAR.S254897. eCollection 2020.
The aim of this study was to investigate the monitoring value of serum HER2 in patients with metastatic breast cancer.
We firstly evaluated the association of serum HER2 levels with tissue HER2 expression and imaging results in 420 breast cancer patients admitted into Tianjin Medical University Cancer Institute and Hospital between April 2016 and December 2018. Secondly, we analyzed serum HER2 levels in breast cancer patients with different metastatic degrees.
There is a higher correlation between serum HER2 and tissue HER2 in breast cancer patients with stage III (κ=0.670, 0.001) and stage IV (κ=0.464, 0.001). Serum HER2 levels were significantly associated with imaging results (κ=0.478, 0.001). The ROC curve analysis showed that serum HER2 was superior to other serum markers for predicting metastatic breast cancer. Multinomial logistic regression revealed that the patients with higher serum HER2 levels would be more likely to have breast cancer metastasis.
Serum HER2 levels in breast cancer patients can partly reflect tissue HER2 expression and tumor imaging changes, and serum HER2 may be used as a biomarker for evaluating metastatic status in patients with breast cancer.
本研究旨在探讨血清HER2在转移性乳腺癌患者中的监测价值。
我们首先评估了2016年4月至2018年12月期间入住天津医科大学肿瘤医院的420例乳腺癌患者血清HER2水平与组织HER2表达及影像学结果之间的关联。其次，我们分析了不同转移程度乳腺癌患者的血清HER2水平。
Ⅲ期（κ=0.670，P=0.001）和Ⅳ期（κ=0.464，P=0.001）乳腺癌患者血清HER2与组织HER水平之间存在较高相关性。血清HER2水平与影像学结果显著相关（κ=0.478，P=0.001）。ROC曲线分析表明，血清HER2在预测转移性乳腺癌方面优于其他血清标志物。多项逻辑回归显示，血清HER2水平较高的患者更有可能发生乳腺癌转移。
乳腺癌患者血清HER2水平可部分反映组织HER2表达及肿瘤影像学变化，血清HER2可作为评估乳腺癌患者转移状态的生物标志物。
